1．フィーダー細胞なしでHER2-CAR-NKT-iPSからHER2-CAR-iPSNKTができたこととその細胞が抗腫瘍効果をマウスでも持つことを示したこと
CAR-iPSCs were successfully differentiated into iNKT cells without compromising the expression of HER2-CAR under the feeder cell-free condition.
Furthermore, the differentiated CAR-iNKT cells derived from CAR-iPSC showed potent anti-tumor effects both in vitro and in vivo.
2．ゼノグラフト(異種移植)マウスモデルで腫瘍縮小ではなく延命を確認できたこと
In the SK-OV-3 xenograft model, the mice in the HER2 CAR-iNKT treatment group survived longer than those in the control or non-CAR introduced iNKT cell treatment groups.
おはようございます
HER2-CAR-iPSNKTのSITC2023での発表は
以下の点に注目です
1．フィーダー細胞なしでHER2-CAR-NKT-iPSからHER2-CAR-iPSNKTができたこととその細胞が抗腫瘍効果をマウスでも持つことを示したこと
CAR-iPSCs were successfully differentiated into iNKT cells without compromising the expression of HER2-CAR under the feeder cell-free condition.
Furthermore, the differentiated CAR-iNKT cells derived from CAR-iPSC showed potent anti-tumor effects both in vitro and in vivo.
2．ゼノグラフト(異種移植)マウスモデルで腫瘍縮小ではなく延命を確認できたこと
In the SK-OV-3 xenograft model, the mice in the HER2 CAR-iNKT treatment group survived longer than those in the control or non-CAR introduced iNKT cell treatment groups.
先はまだまだ長いのですが、順調にCAR-iPSNKTのプラットフォームの実証が進んでいます
非臨床POCが確認できたと言うことを抄録は示しております